NASDAQ: PMN
Promis Neurosciences Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their PMN stock forecasts and price targets.

Forecast return on equity

Is PMN forecast to generate an efficient return?

Company
76.41%
Industry
154.62%
Market
89.47%
PMN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PMN forecast to generate an efficient return on assets?

Company
22.67%
Industry
32.61%
PMN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PMN revenue forecast

What is PMN's revenue in the next 1 years based on estimates from 1 analyst?

Avg 1 year Forecast
$105.8M

PMN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PMN$0.64N/AN/A
PTN$0.81$7.00+765.27%Buy
BIVI$1.12N/AN/A
LSTA$2.38$15.00+530.25%Buy
NNVC$1.30N/AN/A

Promis Neurosciences Stock Forecast FAQ

What is PMN's revenue growth forecast for 2029-2029?

(NASDAQ: PMN) Promis Neurosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 60.56%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.84%.

Promis Neurosciences's revenue in 2025 is $0.

In 2029, PMN is forecast to generate $3,459,823,870 in revenue, with the lowest revenue forecast at $3,459,823,870 and the highest revenue forecast at $3,459,823,870.

If you're new to stock investing, here's how to buy Promis Neurosciences stock.

What is PMN's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: PMN) forecast ROA is 22.67%, which is lower than the forecast US Biotechnology industry average of 32.61%.

What is PMN's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: PMN) forecast ROE is 76.41%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.